Filing Flows › TG Therapeutics (TGTX) › R&D spending
TG Therapeutics (TGTX) R&D spending by quarter
TG Therapeutics' R&D spending was $95.3M in Q2 2026 (second quarter 2026), +97% from Q1 2026. Over the last 7 quarters it ranged from $23.9M (Q4 2024) to $95.3M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $95.3M | +97% | +200% |
| Q1 2026 | $48.4M | +17% | +4% |
| Q4 2025 | $41.2M | +0.8% | +73% |
| Q3 2025 | $40.9M | +29% | — |
| Q2 2025 | $31.8M | -31% | — |
| Q1 2025 | $46.4M | +94% | — |
| Q4 2024 | $23.9M | — | — |
Q2 2026 at a glance
TG Therapeutics, Q2 2026: revenue $240M (+70% year over year), operating margin 9.0%, net earnings $7.8M, operating cash flow $39.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is TG Therapeutics' R&D spending?
TG Therapeutics' R&D spending was $95.3M in Q2 2026 (second quarter 2026), +97% from Q1 2026.
How has TG Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $23.9M (Q4 2024) to $95.3M (Q2 2026).